

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION  
DISCLOSURE STATEMENT**

Docket Number:  
**1662/546051**

Application Number  
**10/669,272**

Filing Date  
**September 23, 2003**

Examiner

Art Unit  
**Not Yet Assigned**

Invention Title  
**PREPARATION OF RISPERIDONE**

Inventors  
**KROCHMAL et al.**

Address to:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450  
on

Date: 2/18/04 Reg. No. 46,877  
Signature: *[Signature]*

Sir:

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following references, to the attention of the Examiner. These references are listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. Applicants' attorney certifies that the below items of information contained in the information disclosure statement were first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of information disclosure statement. The information was contained in a Third Party Observation filed in the counterpart European Application No. 01963971.5.

O.M. Peeters et al., Structure of 3--{2-[4-(6-Fluoro-1,2-benzisoxazole-3-yl) piperidino]ethyl}--6,7,8,9-tetrahydro-2-methyl-4-H-pyrido-[1,2- $\alpha$ ]pyrimidin-4-one (Risperidone), Acta Crystallographica (1993), Section C49, 1698-1700.

US 2002/0193386 A1

3. It is believed that no fees are due in connection with this Information Disclosure Statement. However, should any fees be due, the Commissioner is authorized to charge Deposit Account No. 11-0600 for such fees. A duplicate copy of this communication is enclosed for charging purposes.
4. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.

Dated: 2/18/04

By: \_\_\_\_\_

Siu K. Lo  
Siu K. Lo (Reg. No. 46,877)

KENYON & KENYON


One Broadway

New York, N.Y. 10004

(212) 425-7200 (telephone)

(212) 425-5288 (facsimile)

CUSTOMER NUMBER 26646



**SUPPLEMENTAL  
INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
PTO-1449

**DOCKET NO.**  
1662/546051

**SERIAL NO.**  
10/669,272

**APPLICANT**  
Krochmal, et al.

**FILING DATE**  
September 23, 2003

**GROUP**  
Not Yet Assigned

**U. S. PATENT DOCUMENTS**

EXAMINER INITIAL	PUBLICATION NUMBER	PUBLICATION DATE	NAME	CLASS	SUBCLASS	FILING DATE
	2002/0193386 A1	Dec. 19, 2002	Pfeiffer et al.			

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

**OTHER DOCUMENTS**

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		O.M. Peeters et al., Structure of 3--{2-[4-(6-Fluoro-1,2-benzisoxazole-3-yl) piperidino]ethyl}--6,7,8,9-tetrahydro-2-methyl-4-H-pyrido-[1,2- $\alpha$ ]pyrimidin-4-one (Risperidone), Acta Crystallographica (1993), Section C49, 1698-1700.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	